Precision health focuses on improving overall health and preventing disease, rather than treating disease. Using individual patient information like genetics, environmental and psychosocial factors, and lifestyle, precision health as an emerging discipline seeks to predict illness and to keep people healthy. One of the major goals of precision health is to re-engineer, and ultimately transition, a health system focused on reactive “sick care” to one focused on proactive “health care.”
Through interviews with key opinion leaders, systems-based analyses, and a funder’s summit, the Milken Institute Center for Strategic Philanthropy identified three barriers to implementing precision health ideas and technologies within medical practice, along with key funding opportunities to address each barrier.
The three greatest barriers are:
Insufficient scientific evidence
Insufficient data sharing among relevant health partners
Lack of field-wide coordination
This Giving Smarter Guide outlines potential solutions to each problem, which will help move the field of precision health forward and into the mainstream.
We recommend the following steps:
Promote the development and standardization of precision health tools
Support the development of and continued use of medically-validated measures to record daily functioning, lifestyle, and environmental factors to quantify health
Explore the cost-effectiveness of measurements in existing longitudinal cohorts
Create specialized data platforms to facilitate data sharing in addition to funding data gathering, storing, analyzing, and sharing
Develop an organization focused exclusively on precision health
Throughout the COVID-19 crisis, scientists, policymakers, health-care workers, and average citizens worldwide mobilized in ways never seen before to mitigate the challenge at hand. From rapid vaccine development to securing PPE and...
The challenges that science strives to solve are increasingly complex, and making progress toward them requires constant innovation and the expertise of multiple fields of study. Interdisciplinary research drives this innovation by bringing...
The Biswas Family Foundation and the Milken Institute are pleased to announce the five research teams selected to receive funding in the first cycle of the Transformative Computational Biology Grant Program. Almost $14 million has been...
Computational tools can rapidly identify patterns in vast volumes of biomedical and clinical data, leading to discoveries that can transform the diagnosis, treatment, and prevention of diseases to improve human health. While the scientific...
Shepherding a drug from discovery to the market is a complex process that involves many actors. The process often begins with academic researchers making a breakthrough discovery in the lab and ends with pharmaceutical companies running...
Making an Impact. Strategic philanthropic investments in medical research require a careful consideration of the philanthropist’s priorities and an understanding of the current state of research to amplify the impact of their giving. This...
Imagine living with a disease so mysterious that few people have heard of it—yet it shapes every part of your daily life. For millions of people living with rare or poorly understood health conditions, their (often devastating) symptoms are...
Associate Director, Science Philanthropy Accelerator for Research and Collaboration (SPARC) team, Milken Institute Strategic Philanthropy
Quinton Banks,PhD, is an associate director on the Science Philanthropy Accelerator for Research and Collaboration (SPARC) team at Milken Institute Strategic Philanthropy. His extensive scientific background includes research into chronic pain, taste perception, and muscle physiology.
February 20, 2026 (Washington, DC)—The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a future...
The Ann Theodore Foundation (ATF) is launching a new funding program to support the study of repurposed mechanistic target of rapamycin (mTOR) inhibitors as treatments for cutaneous sarcoidosis. This program will be executed in partnership...